Search results for "embolism"

showing 10 items of 457 documents

D-dimer for risk stratification in haemodynamically stable patients with acute pulmonary embolism

2015

Patients with submassive pulmonary embolism (PE) have a higher short-term mortality than those with low-risk PE. Rapid identification of submassive PE is important for adequate treatment of non-massive PE. We aimed to investigate the utility of D-dimer for the prediction of submassive PE stadium in normotensive PE patients.Normotensive PE patients were classified into submassive or low-risk PE groups. In addition to the comparison of the groups, area under the curve (AUC) and D-dimer cut-off for the prediction of submassive PE stadium, multi-variate logistic regression for association between D-dimer values above this cut-off and submassive PE stadium were also calculated.The data of 129 no…

Malemedicine.medical_specialtyVentricular Dysfunction RightFibrin Fibrinogen Degradation ProductsTachycardiaInternal medicineHeart rateD-dimerHumansMedicineIn patientAgedRetrospective StudiesAged 80 and overbusiness.industryArea under the curveGeneral MedicineMiddle Agedmedicine.diseasePulmonary embolismLogistic ModelsBlood pressureHaemodynamically stableRisk stratificationCardiologyFemalePulmonary EmbolismbusinessAdvances in Medical Sciences
researchProduct

Right ventricular dysfunction in hemodynamically stable patients with acute pulmonary embolism

2013

Abstract Background Echocardiography for risk stratification in hemodynamically stable patients with pulmonary embolism (PE) is well-established. Right ventricular dysfunction (RVD) is associated with an elevated mortality and adverse outcome. The aim of our study was to compare RVD criteria and investigate the role of elevated systolic pulmonary artery pressure (sPAP) in the diagnosis of RVD. Methods We retrospectively analyzed the echocardiographic and laboratory data of all hemodynamically stable patients with confirmed PE (2006-2011). The data were compared with three different definitions of RVD: Definition 1: RV dilatation, abnormal motion of interventricular septum, RV hypokinesis or…

Malemedicine.medical_specialtyVentricular Dysfunction RightInternal medicinemedicine.arteryTroponin ImedicineHumansInterventricular septumAgedRetrospective StudiesAged 80 and overmedicine.diagnostic_testbiologyVentilation/perfusion scanbusiness.industryTroponin IHeartHematologyMiddle AgedRight bundle branch blockPrognosismedicine.diseaseTroponinPulmonary embolismmedicine.anatomical_structureEchocardiographyAcute DiseasePulmonary arterybiology.proteinCardiologyFemalePulmonary EmbolismbusinessElectrocardiographyThrombosis Research
researchProduct

Experience in daily clinical practice of ambulatory cardioversion of atrial fibrillation treated with new oral anticoagulants.

2014

Malemedicine.medical_specialtyVitamin Kbusiness.industrymedicine.medical_treatmentElectric CountershockAdministration OralAnticoagulantsAtrial fibrillationGeneral Medicinemedicine.diseaseCardioversionClinical PracticeThromboembolismAmbulatoryAtrial FibrillationmedicineAmbulatory CareHumansFemaleIntensive care medicinebusinessAgedRetrospective StudiesRevista espanola de cardiologia (English ed.)
researchProduct

Psoriasis and its impact on the clinical outcome of patients with pulmonary embolism

2021

Abstract Background Venous thromboembolism (VTE) is common and associated with high morbidity and mortality. Although chronic inflammation was not categorized as a traditional risk factor for VTE, chronic inflammation might increase the risk to develop VTE events. While studies confirmed an increased cardiovascular morbidity and mortality in psoriatic patients, data regarding the influence of psoriasis on patients' cardiovascular profile and on prognosis of patients with pulmonary embolism (PE) are sparse. Purpose We aimed to investigate the impact of psoriasis on prognosis of PE patients. Methods Hospitalized PE patients were stratified for psoriasis and the impact of psoriasis on outcome …

Malemedicine.medical_specialtyYounger agebusiness.industryVenous Thromboembolismmedicine.diseasePulmonary embolismVenous thrombosisIncreased riskRisk FactorsInternal medicinePsoriasismedicineHumansPsoriasisFemaleHospital MortalityPulmonary EmbolismCardiology and Cardiovascular MedicinebusinessVenous thromboembolismAgedEuropean Heart Journal
researchProduct

Acute inferior myocardial infarction due to a large thrombus in the Left coronary sinus of valsalva.

2021

Background Masses in the ascending aorta are an uncommon source of coronary embolism: thrombi located on atherosclerotic aortic plaques are the most frequent cause. A floating thrombus, without evidence of ascending aortic pathology has rarely been reported Method We report a case of an unusual aortic route thromboembolism leading ST segment elevation Myocardial Infarction (STEMI). The patient was referred to the Hub Hospital to undergo urgent coronarography. The examination excluded atherosclerotic coronary arteries disease but an unusual persistence of contrast dye was found at the level of non-coronary sinus. The trans-esophageal echocardiography showed a mobile pedunculated echogenic ma…

Malemedicine.medical_specialtybusiness.industryAcute Inferior Myocardial InfarctionThrombosisGeneral MedicineInferior Wall Myocardial InfarctionSinus of ValsalvaCoronary embolismmedicine.diseaseInternal medicinemedicineCardiologyHumansThrombusMyocardial Infarction with Non Obstructive Coronary Artery (MINOCA) Aortic routeThrombectomy Coronary EmbolismCardiology and Cardiovascular MedicinebusinessCoronary sinusAgedCoronary artery disease
researchProduct

Clinical course of isolated distal deep vein thrombosis in patients with active cancer: a multicenter cohort study

2017

Essentials Isolated distal deep vein thrombosis (IDDVT) is frequently associated with cancer. No study has specifically evaluated the long-term clinical course of cancer-associated IDDVT. Patients with cancer-associated IDDVT are at very high risk of symptomatic recurrence and death. We observed low rates of major bleeding during anticoagulation. SummaryBackground Although isolated distal deep vein thrombosis (IDDVT) is frequently associated with cancer, no study has specifically evaluated the long-term clinical course of IDDVT in this setting. Aim To provide data on the rate of recurrent venous thromboembolism (VTE), major bleeding events and death in IDDVT patients with active cancer. Pat…

Malemedicine.medical_specialtydistal deep vein thrombosis; mortality; neoplasm; observational study; venous thromboembolism; HematologyTime FactorsDeep veinHemorrhage030204 cardiovascular system & hematologyDisease-Free Survival03 medical and health sciences0302 clinical medicineRecurrenceRisk FactorsNeoplasmsInternal medicinemedicineHumans030212 general & internal medicineAgedProportional Hazards ModelsRetrospective StudiesVenous ThrombosisHematologybusiness.industryIncidenceClinical courseAnticoagulantsCancerdistal deep vein thrombosiVenous ThromboembolismHematologyHeparinMiddle Agedmedicine.diseasemortalityThrombosisSurgeryTreatment Outcomemedicine.anatomical_structureItalyobservational studyFemaledistal deep vein thrombosisPulmonary EmbolismbusinessVenous thromboembolismneoplasmDistal deep vein thrombosis; Mortality; Neoplasm; Observational study; Venous thromboembolism; Hematologymedicine.drugCohort studyJournal of Thrombosis and Haemostasis
researchProduct

Risk factors for chronic thromboembolic pulmonary hypertension – Importance of thyroid disease and function

2019

Abstract Introduction Although a number of risk factors for chronic thromboembolic pulmonary hypertension (CTEPH) have been reported, the exact prevalence is controversial and varies between published cohorts. The aim of the present study was to investigate the prevalence of risk factors in operable CTEPH patients with special emphasis on thyroid disease and function. Material and methods Overall, 228 CTEPH patients (47.7% female; median age 63 [IQR 52–72] years) scheduled for pulmonary endarterectomy between 01/2014 and 12/2015 were studied. Prevalence of risk factors was assessed, and patients were classified according to their thyroid function based on laboratory measurements. Results As…

Malemedicine.medical_specialtyendocrine system diseasesHypertension PulmonaryLevothyroxineCardiac index030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumansEuthyroidRisk factorAgedbusiness.industryThyroid diseaseHematologyMiddle Agedmedicine.diseaseThyroid DiseasesPulmonary embolism030220 oncology & carcinogenesisChronic DiseaseFemaleChronic thromboembolic pulmonary hypertensionThyroid functionPulmonary Embolismbusinessmedicine.drugThrombosis Research
researchProduct

The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry

2017

Abstract Introduction The appropriate strategy for initiating oral anticoagulant (OAC) therapy after an acute venous thromboembolism (VTE) depends on the intermediate-term anticoagulant to be used. While heparin bridging to vitamin K antagonists (VKA) is required, the direct oral anticoagulants (DOAC) rivaroxaban (30 mg/day) and apixaban (10 mg/day) can be initiated directly without parenteral anticoagulation. The objective was to evaluate OAC initiation patterns in clinical practice. Materials and methods PREFER in VTE was an international, non-interventional registry conducted between January 2013 and August 2015. Consecutive acute VTE patients were grouped based on their OAC treatment at…

Malemedicine.medical_specialtymedicine.drug_class030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRivaroxabanInternal medicinemedicineHumansRegistries030212 general & internal medicineIntensive care medicineLead (electronics)RivaroxabanAnticoagulants; Heparin; Rivaroxaban; Venous thromboembolism; Warfarin; Acute Disease; Anticoagulants; Female; Heparin; Humans; Male; Middle Aged; Registries; Venous Thromboembolism; HematologyHeparinbusiness.industryAnticoagulantWarfarinAnticoagulantsVenous ThromboembolismHematologyHeparinMiddle Agedmedicine.diseasePulmonary embolismAcute DiseaseFemaleApixabanWarfarinbusinessVenous thromboembolismmedicine.drugThrombosis Research
researchProduct

Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II)

2010

SummaryThis trial compared the efficacy and safety of oral dabigatran, a direct thrombin inhibitor, versus subcutaneous enoxaparin for extended thromboprophylaxis in patients undergoing total hip arthroplasty. A total of 2,055 patients were randomised to 28–35 days treatment with oral dabigatran, 220 mg once-daily, starting with a half-dose 1–4 hours after surgery, or subcutaneous enoxaparin 40 mg once-daily, starting the evening before surgery. The primary efficacy outcome was a composite of total venous thromboembolism [VTE] (venographic or symptomatic) and death from all-causes. The main secondary composite outcome was major VTE (proximal deep-vein thrombosis or non-fatal pulmonary embol…

Malemedicine.medical_specialtymedicine.drug_classArthroplasty Replacement HipInjections SubcutaneousAdministration OralLow molecular weight heparinHemorrhage030226 pharmacology & pharmacyAntithrombinsDabigatranlaw.invention03 medical and health sciencesPostoperative Complicationsoral thromboprophylaxis dabigatran flebography0302 clinical medicineDouble-Blind MethodRandomized controlled triallawHumansMedicineEnoxaparinAgedVenous Thrombosisbusiness.industryAnticoagulantAnticoagulantsVenous ThromboembolismHematologyMiddle Agedmedicine.diseaseSurvival AnalysisDabigatranSurgeryPulmonary embolismVenous thrombosisDirect thrombin inhibitorAnesthesiabeta-AlanineBenzimidazolesFemalebusinessEnoxaparin sodiummedicine.drugThrombosis and Haemostasis
researchProduct

Perioperative and Periprocedural Management of Antithrombotic Therapy: Consensus Document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH…

2018

During the last few years, the number of patients receiving anticoagulant and antiplatelet therapy has increased worldwide. Since this is a chronic treatment, patients receiving it can be expected to need some kind of surgery or intervention during their lifetime that may require treatment discontinuation. The decision to withdraw antithrombotic therapy depends on the patient's thrombotic risk versus hemorrhagic risk. Assessment of both factors will show the precise management of anticoagulant and antiplatelet therapy in these scenarios. The aim of this consensus document, coordinated by the Cardiovascular Thrombosis Working Group of the Spanish Society of Cardiology, and endorsed by most o…

Malemedicine.medical_specialtymedicine.drug_classHemorrhage030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRisk FactorsThromboembolismIntervention (counseling)Preoperative CareAntithromboticmedicineHumans030212 general & internal medicineIntensive care medicineAgedAged 80 and overThrombotic riskIntraoperative CareDrug Substitutionbusiness.industryAnticoagulantAnticoagulantsGeneral MedicinePerioperativemedicine.diseaseThrombosisDiscontinuationConventional PCIFemaleAntiagregación Anticoagulación Anticoagulation Antiplatelet Antithrombotic Antitrombótico Cirugía SurgerybusinessPlatelet Aggregation InhibitorsRevista Española de Cardiología (English Edition)
researchProduct